Equity awards for BioNTech (NASDAQ: BNTX) officer disclosed

Rhea-AI Filing Summary

BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.

The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ryan James Timothy Patrick

Role See remarks.

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	12,586	$0.00	--
Grant/Award	Performance Share Unit	10,069	$0.00	--

Holdings After Transaction: Option (right to buy) — 12,586 shares (Direct, null); Performance Share Unit — 10,069 shares (Direct, null)

Footnotes (1)

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Key Figures

Performance Share Units granted: 10,069 units Options granted: 12,586 shares Option exercise price: EUR 89.38 per share +2 more

5 metrics

Performance Share Units granted 10,069 units Grant on May 12, 2026

Options granted 12,586 shares Option (right to buy) on May 12, 2026

Option exercise price EUR 89.38 per share Subject to adjustment tied to ADS trading price

Vesting schedule 4 annual installments over 4 years Commencing on first anniversary of grant date

Expiration date May 12, 2036 Option and PSU expiration

Key Terms

Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, exercise price, +1 more

5 terms

Performance Share Unit financial

"Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

American Depositary Share financial

"Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Nasdaq Biotechnology Index financial

"performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

exercise price financial

"The exercise price of this option is EUR 89.38."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

performance-based conditions financial

"becomes exercisable four years after the grant date, subject to certain performance-based and other conditions."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan James Timothy Patrick

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	05/12/2026		A		12,586		05/12/2030(2)	05/12/2036	Ordinary Shares(3)	12,586	$0	12,586	D
Performance Share Unit	$0	05/12/2026		A		10,069		05/12/2030(4)	05/12/2036	Ordinary Shares(4)	10,069	$0	10,069	D

Explanation of Responses:

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

Chief Legal Officer and Chief Business Officer

	/s/ Humza Bokhari, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did BioNTech (BNTX) grant to Ryan James Timothy Patrick?

BioNTech granted Ryan James Timothy Patrick 10,069 Performance Share Units and an option over 12,586 ordinary shares. These awards are part of his compensation package and are subject to multi-year vesting schedules and performance or service conditions before they can be exercised or settled.

What is the exercise price of the new BioNTech option grant reported for BNTX?

The option granted to the BioNTech officer has an exercise price of EUR 89.38 per share. It was issued with a grant price of zero, but must be paid at this exercise price when exercised, subject to adjustment tied to the trading price of the company’s ADSs.

How do the BioNTech (BNTX) Performance Share Units for this officer vest and settle?

Each Performance Share Unit is economically equivalent to one ordinary share and vests annually in equal installments over four years. Upon vesting and exercise, BioNTech may settle each PSU in an ordinary share, one ADS, cash, or another form equal to its economic value.

What performance conditions apply to the BioNTech PSUs granted in this Form 4?

The PSUs are subject to performance targets based on the market price of BioNTech’s ordinary shares relative to the Nasdaq Biotechnology Index. Vesting also requires the reporting person’s continued service through each vesting date, making both market performance and tenure key factors.

When do the BioNTech option and PSUs granted to the officer become exercisable?

Both the option and the PSUs vest in equal annual installments over four years, starting on the first anniversary of the grant date. They become exercisable four years after the grant date, assuming all specified performance-based and other service conditions have been satisfied by that time.